Literature DB >> 21896638

Ablation of sphingosine kinase-2 inhibits tumor cell proliferation and migration.

Peng Gao1, Charles D Smith.   

Abstract

Sphingosine kinases (SK) regulate the balance between proapoptotic ceramides and mitogenic sphingosine-1-phosphate (S1P); however, the functions of the two isoenzymes (SK1 and SK2) in tumor cells are not well defined. Therefore, RNA interference was used to assess the individual roles of SK1 and SK2 in tumor cell sphingolipid metabolism, proliferation, and migration/invasion. Treatment of A498, Caki-1, or MDA-MB-231 cells with siRNAs specific for SK1 or SK2 effectively suppressed the expression of the target mRNA and protein. Ablation of SK1 did not affect mRNA or protein levels of SK2 and reduced intracellular levels of S1P while elevating ceramide levels. In contrast, ablation of SK2 elevated mRNA, protein, and activity levels of SK1 and increased cellular S1P levels. Interestingly, cell proliferation and migration/invasion were suppressed more by SK2-selective ablation than by SK1-selective ablation, showing that the increased S1P does not rescue these phenotypes. Similarly, exogenous S1P did not rescue the cells from the antiproliferative or antimigratory effects of the siRNAs. Consistent with these results, differential effects of SK1- and SK2-selective siRNAs on signaling proteins, including p53, p21, ERK1, ERK2, FAK, and VCAM1, indicate that SK1 and SK2 have only partially overlapping functions in tumor cells. Overall, these data indicate that loss of SK2 has stronger anticancer effects than does suppression of SK1. Consequently, selective inhibitors of SK2 may provide optimal targeting of this pathway in cancer chemotherapy. Mol Cancer Res; 9(11); 1509-19. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21896638      PMCID: PMC3219805          DOI: 10.1158/1541-7786.MCR-11-0336

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  53 in total

1.  SphK1 and SphK2, sphingosine kinase isoenzymes with opposing functions in sphingolipid metabolism.

Authors:  Michael Maceyka; Heidi Sankala; Nitai C Hait; Hervé Le Stunff; Hong Liu; Rachelle Toman; Claiborne Collier; Min Zhang; Leslie S Satin; Alfred H Merrill; Sheldon Milstien; Sarah Spiegel
Journal:  J Biol Chem       Date:  2005-08-23       Impact factor: 5.157

Review 2.  Mechanisms of ceramide-mediated apoptosis.

Authors:  Y A Hannun; L M Obeid
Journal:  Adv Exp Med Biol       Date:  1997       Impact factor: 2.622

3.  Sphingosine kinase 2 is required for modulation of lymphocyte traffic by FTY720.

Authors:  Yugesh Kharel; Sangderk Lee; Ashley H Snyder; Stacey L Sheasley-O'neill; Margaret A Morris; Yulius Setiady; Ran Zhu; Molly A Zigler; Tracy L Burcin; Klaus Ley; Kenneth S K Tung; Victor H Engelhard; Timothy L Macdonald; Sonia Pearson-White; Kevin R Lynch
Journal:  J Biol Chem       Date:  2005-08-10       Impact factor: 5.157

4.  Role of sphingosine kinase 2 in cell migration toward epidermal growth factor.

Authors:  Nitai C Hait; Sukumar Sarkar; Hervé Le Stunff; Aki Mikami; Michael Maceyka; Sheldon Milstien; Sarah Spiegel
Journal:  J Biol Chem       Date:  2005-06-10       Impact factor: 5.157

5.  Sphingosine kinase 1 is required for migration, proliferation and survival of MCF-7 human breast cancer cells.

Authors:  Sukumar Sarkar; Michael Maceyka; Nitai C Hait; Steven W Paugh; Heidi Sankala; Sheldon Milstien; Sarah Spiegel
Journal:  FEBS Lett       Date:  2005-10-10       Impact factor: 4.124

6.  Effects of p21(Cip1/Waf1) at both the G1/S and the G2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication.

Authors:  A B Niculescu; X Chen; M Smeets; L Hengst; C Prives; S I Reed
Journal:  Mol Cell Biol       Date:  1998-01       Impact factor: 4.272

7.  Sphingosine kinase 1 is up-regulated in colon carcinogenesis.

Authors:  Toshihiko Kawamori; Walid Osta; Korey R Johnson; Benjamin J Pettus; Jacek Bielawski; Takuji Tanaka; Michael J Wargovich; Bandaru S Reddy; Yusuf A Hannun; Lina M Obeid; Daohong Zhou
Journal:  FASEB J       Date:  2005-11-30       Impact factor: 5.191

8.  Sphingosine kinase-1 expression correlates with poor survival of patients with glioblastoma multiforme: roles of sphingosine kinase isoforms in growth of glioblastoma cell lines.

Authors:  James R Van Brocklyn; Catherine A Jackson; Dennis K Pearl; Mark S Kotur; Pamela J Snyder; Thomas W Prior
Journal:  J Neuropathol Exp Neurol       Date:  2005-08       Impact factor: 3.685

9.  Mice deficient in sphingosine kinase 1 are rendered lymphopenic by FTY720.

Authors:  Maria L Allende; Teiji Sasaki; Hiromichi Kawai; Ana Olivera; Yide Mi; Gerhild van Echten-Deckert; Richard Hajdu; Mark Rosenbach; Carol Ann Keohane; Suzanne Mandala; Sarah Spiegel; Richard L Proia
Journal:  J Biol Chem       Date:  2004-09-30       Impact factor: 5.157

10.  Phosphorylation-dependent translocation of sphingosine kinase to the plasma membrane drives its oncogenic signalling.

Authors:  Stuart M Pitson; Pu Xia; Tamara M Leclercq; Paul A B Moretti; Julia R Zebol; Helen E Lynn; Binks W Wattenberg; Mathew A Vadas
Journal:  J Exp Med       Date:  2004-12-28       Impact factor: 14.307

View more
  46 in total

1.  Downregulation of Critical Oncogenes by the Selective SK2 Inhibitor ABC294640 Hinders Prostate Cancer Progression.

Authors:  Randy S Schrecengost; Staci N Keller; Matthew J Schiewer; Karen E Knudsen; Charles D Smith
Journal:  Mol Cancer Res       Date:  2015-08-13       Impact factor: 5.852

Review 2.  Evolving concepts in cancer therapy through targeting sphingolipid metabolism.

Authors:  Jean-Philip Truman; Mónica García-Barros; Lina M Obeid; Yusuf A Hannun
Journal:  Biochim Biophys Acta       Date:  2013-12-30

3.  Novel sphingosine-containing analogues selectively inhibit sphingosine kinase (SK) isozymes, induce SK1 proteasomal degradation and reduce DNA synthesis in human pulmonary arterial smooth muscle cells.

Authors:  Hoe-Sup Byun; Susan Pyne; Neil Macritchie; Nigel J Pyne; Robert Bittman
Journal:  Medchemcomm       Date:  2013       Impact factor: 3.597

4.  A Phase I Study of ABC294640, a First-in-Class Sphingosine Kinase-2 Inhibitor, in Patients with Advanced Solid Tumors.

Authors:  Carolyn D Britten; Elizabeth Garrett-Mayer; Steven H Chin; Keisuke Shirai; Besim Ogretmen; Tricia A Bentz; Alan Brisendine; Kate Anderton; Susan L Cusack; Lynn W Maines; Yan Zhuang; Charles D Smith; Melanie B Thomas
Journal:  Clin Cancer Res       Date:  2017-04-18       Impact factor: 12.531

Review 5.  Interdiction of sphingolipid metabolism to improve standard cancer therapies.

Authors:  Thomas H Beckham; Joseph C Cheng; S Tucker Marrison; James S Norris; Xiang Liu
Journal:  Adv Cancer Res       Date:  2013       Impact factor: 6.242

Review 6.  Targeting the sphingosine kinase/sphingosine 1-phosphate pathway in disease: review of sphingosine kinase inhibitors.

Authors:  K Alexa Orr Gandy; Lina M Obeid
Journal:  Biochim Biophys Acta       Date:  2012-07-16

7.  Sphingosine-1-phosphate links persistent STAT3 activation, chronic intestinal inflammation, and development of colitis-associated cancer.

Authors:  Jie Liang; Masayuki Nagahashi; Eugene Y Kim; Kuzhuvelil B Harikumar; Akimitsu Yamada; Wei-Ching Huang; Nitai C Hait; Jeremy C Allegood; Megan M Price; Dorit Avni; Kazuaki Takabe; Tomasz Kordula; Sheldon Milstien; Sarah Spiegel
Journal:  Cancer Cell       Date:  2012-12-27       Impact factor: 31.743

8.  The roles of sphingosine kinases 1 and 2 in regulating the Warburg effect in prostate cancer cells.

Authors:  David G Watson; Francesca Tonelli; Manal Alossaimi; Leon Williamson; Edmond Chan; Irina Gorshkova; Evgeny Berdyshev; Robert Bittman; Nigel J Pyne; Susan Pyne
Journal:  Cell Signal       Date:  2013-01-11       Impact factor: 4.315

9.  FTY720 inhibits tumor growth and enhances the tumor-suppressive effect of topotecan in neuroblastoma by interfering with the sphingolipid signaling pathway.

Authors:  Mei-Hong Li; Timothy Hla; Fernando Ferrer
Journal:  Pediatr Blood Cancer       Date:  2013-05-23       Impact factor: 3.167

10.  Down-regulation of Sphk2 suppresses bladder cancer progression.

Authors:  Erlin Sun; Wenbo Zhang; Lining Wang; Aixiang Wang; Chengquan Ma; Mingde Lei; Xiaodong Zhou; Yan Sun; Bingxin Lu; Liwei Liu; Ruifa Han
Journal:  Tumour Biol       Date:  2015-07-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.